Tumor Budding: Prognostic Value in Muscle-invasive Bladder Cancer
Autores de IIS La Fe
Grupos
Abstract
OBJETIVES To assess if "tumor budding" (TB) behaves as a poor prognostic factor in muscle-invasive bladder carcinoma (MIBC). TB is the presence of tumor cells isolated or in small groups of fewer than 5 cells located at the tumor invasion front. MATERIAL AND METHODS Retrospective study of 106 patients with MIBC who underwent radical cystectomy. A cytokeratin AE1/AE3 immunostaining was applied to identify and quantify TB by the "hot-spot" method. The variables evaluated were: age, gender, Tumour, Node, Metastasis Classification (TNM) stage, associated Carcinoma in situ, differentiation degree, tumor size, tumor location, lymphatic, venous or perineural invasion, p53, Ki67, molecular subtype (basal/luminal) and chemotherapy. Main variables were overall and cancer-specific survival. RESULTS The mean follow-up time was 47 +/- 46.45 months. The mean TB count was 32.3 +/- 25.9 "buds." The ROC curve established 14 "buds" as the cut-off point: the median survival rate for the "low-grade TB" group (<= 14 "buds") was 69.5 months, and for the "high-grade TB" group (>14 "buds") was 18.5 months (P= .003). In the multivariate analysis, independent predictive variables regarding mortality were: age, TB, and TNM stage. Patients with more than 14 "buds" had 2.27 times more risk of mortality, 95%CI:1.19-4.34, P = .013. In addition, the risk of mortality rises progressively as the number of "buds" increases, at a rate of 2% per "bud." CONCLUSION According to our results, TB becomes an independent predictor factor for cancer-specific mortality in MIBC, with a cut-off point of 14 "buds." (C) 2019 Elsevier Inc.
Datos de la publicación
- ISSN/ISSNe:
- 0090-4295, 1527-9995
- Tipo:
- Article
- Páginas:
- 93-98
- PubMed:
- 30986485
- Factor de Impacto:
- 0,854 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Urology ELSEVIER SCIENCE INC
Citas Recibidas en Web of Science: 13
Documentos
- No hay documentos
Filiaciones
Proyectos y Estudios Clínicos
MODELIZACION MATEMATICA DE LOS FACTORES DE RIESGO EN TRES PROBLEMAS DE SALUD PUBLICA: CARCINOMA VESICAL, TABAQUISMO, Y ACCIDENTES DE TRAFICO. VALIDACION Y RECOMENDACIONES PREVENTIVAS
Investigador Principal: JOSE LUIS PONTONES MORENO
PARTIC PI - UPV . 2005
RECEPTOR PEROXISOMA-PROLIFERADOR-ACTIVADO GAMMA (PPAR-?) EN LA REGULACION DE LA INMUNIDAD INNATA Y ADQUIRIDA DELA ENFERMEDAD DE CROHN: UNA ESTRATEGIA TERAPEUTIA DIFERENTE.
Investigador Principal: BELÉN BELTRÁN NICLÓS
PI14/01702 . INSTITUTO DE SALUD CARLOS III . 2015
PROSPET. DISPOSITIVO MULTI-IMAGEN CON UN DETECTOR PET PARA GUIAR LA BIOPSIA, EL TRATAMIENTO Y EL SEGUIMIENTO DEL CÁNCER DE PRÓSTATA.
Investigador Principal: CÉSAR DAVID VERA DONOSO
DTS15/00044 . INSTITUTO DE SALUD CARLOS III . 2016
ESTUDIO DE FASE 3, ALEATORIZADO, CONTROLADO, MULTICÉNTRICO Y ABIERTO, PARA COMPARAR EL TIVOZANIB CLORHIDRATO FRENTE AL SORAFENIB EN SUJETOS CON CARCINOMA DE CÉLULAS RENALES AVANZADO RESISTENTE AL TRATAMIENTO.
Investigador Principal: REGINA GIRONÉS SARRIÓ
AV-951-15-303 . 2016
ENSAYO MULTICÉNTRICO, CONTROLADO Y ALEATORIZADO PARA EVALUAR EL USO COMBINADO DE UN DISPOSITIVO MÉDICO Y UN COMPLEMENTO ALIMENTICIO EN EL CONTROL DEL PH URINARIO DE PACIENTES CON UN CATÉTER DOBLE J IMPLANTADO.
Investigador Principal: ALBERTO BUDÍA ALBA
DEV-LCD-02-17 . 2017
ENSAYO CLÍNICO FASE IB/II SOBRE LA COMBINACIÓN DE GLASDEGIB (INHIBIDOR DE LA VÍA SHH) Y TEMOZOLAMIDA EN PACIENTES CON DIAGNÓSTICO DE NOVO DE GLIOBLASTOMA.
Investigador Principal: REGINA GIRONÉS SARRIÓ
GEINO-1602 . 2018
MATTERHORN - PREVALENCE OF DLL3 EXPRESSION AMONG SCLC PATIENTS UNDER REAL WORLD CONDITIONS.
Investigador Principal: NURIA MANCHEÑO FRANCH
ABB-QUI-2018-01
ESTUDIO EN FASE III ABIERTO, ALEATORIZADO, MULTICÉNTRIDO, ESTRATIFICADO, DE COMPARADOR ACTIVO Y DE GRUPOS PARALELOS PARA COMPARAR EL TRATAMIENTO CON 177LU-DOTA0-TYR3-ACETATO DE OCTREOTIDA FRENTE A OCTREOTIDA DE ACCIÓN PROLONGADA EN PACIENTES CON TUMORES CARCINOIDES DEL INTESTINO MEDIO IRRESECABLES, PROGRESIVOS, POSITIVOS PARA RECEPTORES DE SOMATOSTATINA.
Investigador Principal: PILAR BELLO ARQUES
AAA-III-01 . 2013
Cita
SORIANO LL,JURADO GO,MORENO JLP,CASTILLO SV,GIRON SH,MORENO IS,SOLER DR. Tumor Budding: Prognostic Value in Muscle-invasive Bladder Cancer. Urology. 2019. 130. p. 93-98. IF:1,924. (3).